<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty patients with high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, defined as &gt; 5% bone marrow blasts, were treated with a combination of oral <z:hpo ids='HP_0000001'>all</z:hpo>-trans-<z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles </plain></SENT>
<SENT sid="1" pm="."><plain>Complete remission lasting 9, 12, and 15 months was achieved in three patients </plain></SENT>
<SENT sid="2" pm="."><plain>Partial and minor response did not translate into meaningful clinical improvement, like complete responders </plain></SENT>
<SENT sid="3" pm="."><plain>Overall incidence of <z:hpo ids='HP_0001909'>leukemia</z:hpo> transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics </plain></SENT>
</text></document>